The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | KEYNOTE-585: mPR and tumor downstaging as surrogate endpoints in G/GEJ
Kohei Shitara, MD, National Cancer Center Hospital East, Tokyo, Japan, comments on the post hoc analysis of the KEYNOTE-585 trial (NCT03221426), which examined the utility of major pathologic response (mPR) and pathologic tumor downstaging (pDS) as surrogate endpoints in patients with locally advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ). The study compares neoadjuvant or adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy. Pembrolizumab improved pathologic complete response (pCR) and mPR rates, with numerically better event-free survival (EFS) and overall survival (OS) for patients achieving mPR. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding – Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
